Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators.

N Engl J Med. 2006 Sep 7;355(10):983-91.

2.

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.

Hamilton G, Rath B.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):17-24. doi: 10.1080/17425255.2018.1416095. Epub 2017 Dec 18. Review.

PMID:
29226731
3.

Biological and predictive role of ERCC1 polymorphisms in cancer.

Formica V, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau HT, Guadagni F, Orlandi A, Roselli M.

Crit Rev Oncol Hematol. 2017 Mar;111:133-143. doi: 10.1016/j.critrevonc.2017.01.016. Epub 2017 Jan 28. Review.

PMID:
28259288
4.

Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.

Tao H, Zhang Y, Li Q, Chen J.

J Cancer Res Clin Oncol. 2017 Nov;143(11):2245-2256. doi: 10.1007/s00432-017-2516-1. Epub 2017 Sep 5. Review.

PMID:
28875225

Supplemental Content

Support Center